Literature DB >> 10740121

The role of clinical nonfatal end points in cardiovascular phase II/III clinical trials.

C M O'Connor1, W A Gattis, T J Ryan.   

Abstract

Mesh:

Substances:

Year:  2000        PMID: 10740121     DOI: 10.1016/s0002-8703(00)90062-0

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


× No keyword cloud information.
  2 in total

1.  Analyzing composite outcomes in cardiovascular studies: traditional Cox proportional hazards versus quality-of-life-adjusted survival approaches.

Authors:  Dean T Eurich; Sumit R Majumdar; Finlay A McAlister; Ross T Tsuyuki; Yutaka Yasui; Jeffrey A Johnson
Journal:  Open Med       Date:  2010-02-23

2.  Losartan and diabetic nephropathy: commentaries on the RENAAL study.

Authors:  Enrique Z Fisman; Alexander Tenenbaum; Michael Motro
Journal:  Cardiovasc Diabetol       Date:  2002-04-08       Impact factor: 9.951

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.